直肠癌术前淋巴化疗安全性分析

摘要

Objective To investigate the clinical safety of preoperative lymphatic chemotherapy in the treatment of reetal cancer.Methods The regional and systemic symptoms,postoperatwe stoma healing,haematogenesis.functions of hean,liver and kidney after lymphatic chemotherapy,and the level of CD3+,CD4+,CD8+,CD4+/CD8+,CD(16+56)+in blood 30 minutes before and 48 hours after lymphatic chemotherapv were detected.Results There were no significant effects of lymphatic chemotherapy on the regional and systemic symptoms,postoperative stoma healing,haematogenesis and the functions of heart,liver and kidney.The level of CD4+/CD8+48 hours after lymphatic chemotherapy was significantly increased(t=7.145,P＜0.05),while no significant changes of CD3+,CIM+,CD8+,CD(16+56)+were detected(t=1.782,1.151,1.184,0.955,P＞0.05),when compared with those 30 minutes before lymphatic chemotherapy.Conclusions Preoperative lymphatic chemotherapy is safe and can enhance patients'immunity in early stage.%目的 研究直肠癌患者术前淋巴化疗应用的安全性.方法 观察淋巴化疗后局部和全身症状、心肝肾及造血功能变化、术后吻合口愈合情况以及检测淋巴化疗前30 min和淋巴化疗后48 h血CD3+、CD4+、CD8+、CD4+/CD8+、CD(16+56)+.结果 淋巴化疗对局部和全身症状、心肝肾及造血功能、术后吻合口愈合无明显影响;比较淋巴化疗前30 min与淋巴化疗后48 h,CD4+/CD8+升高(t=7.145,P＜0.05),CD3+、CD4+、CD8+、CD(16+56)+无明显变化(t=1.782,1.151,1.184,0.955,P＞0.05).结论 淋巴化疗具有安全性,短期内对机体免疫有一定促进作用.